Why the study?
Do cytochrome allelic variants (CYP2C19 and CYP3A4/5) impact the clinical efficacy and safety of clopidogrel alone or with proton pump inhibitors in patients with acute coronary syndrome?
Population
Patients with acute coronary syndrome (ACS) and heart attacks treated with clopidogrel
Design
Review
Authors
Loading...
Genetic CYP testing may guide clopidogrel selection in ACS; leaves open whether it improves clinical outcomes.
Do cytochrome allelic variants (CYP2C19 and CYP3A4/5) impact the clinical efficacy and safety of clopidogrel alone or with proton pump inhibitors in patients with acute coronary syndrome?
Genetic polymorphisms in CYP2C19 and CYP3A4/5 are critical factors that modify clopidogrel metabolism and may influence clinical outcomes and drug interactions in ACS patients.
Mohammed Jarrar (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: